Immunothérapie in treatment of cancer
Cancer CAR-NK therapiam efficacem valorem 73% habet, et in iudiciis clinicis domesticis reficitur.
Immunotherapyrum conversio de modo cancri curatur. Cancer immunotherapy in duo genera dividitur: unum est laxis inhibitoria immunis, et PD-1, PD-L1 et CTLA-4 probata sunt ad curationem carcinomata varia. Et anno 2018 Praemium Nobelianum Physiologiae seu Medicinae adiudicavit contributionem evolutionis immunis LAPIS inhibitoribus hominibus.
Altera est immunotherapia cellularis, in qua chimeric antigen receptor CAR-T therapy is the most rapidly progressing one. In 2017, the US Food and Drug Administration (FDA) approved two CAR-T cell therapies, Yescarta and Kymriah, which mainly target hematological tumors, leukemias and lymphomas.
Lorem car T Cell
CAR-T therapy has a long way to go to treat solid tumors, so scientists have begun to seek other cellular immunotherapies to treat cancer, and natural killer (NK) cell therapy is one of the most promising methods. The success of CAR-T cell therapy has stimulated enthusiasm for modifying NK cells with CAR genes to enhance their tumor-killing ability.
Recently, the results of a phase I / IIa trial of the MD Anderson Cancer Center in the United States announced that CD19-targeted umbilical cord blood chimeric antigen receptor natural killer cell therapy (CAR-NK) has achieved a clinical response. No major toxicities were observed in patients with refractory or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
NK, itemque car-cell notitia Lorem investigationis
Eventus hesterno die iudicii erant published in Nova Anglia Acta Medicine. De XI aegros participatione in tablino, VIII (LXXIII%) respondit ad curatio, et VII eorum respondit omnino, nempe quod non ostendit signum de cancer a mediana sequi-sursum of 11 menses et aegris periti cellulas elementum vel neurotoxicity release syndrome.
CD19 responsionis ad NK, itemque car-cell Lorem autem significant in I mensis post infusionem; et quod hae cellulae quo modo adhuc perstet usque nequiquam detecta fraude in I anno post infusionem causet.
Respondentem auctor Michael Rezvani, Professor of Stem Cell translationi et Cell Therapy, dixit: "Nos adhortatus est eventus et orci iudicii, quam Deus praestat adhuc orci studiis studere in potentiale allogeneic funis sanguinem propriae car-NK cellulis quod patientes estote ad opus est in treatment options. '
Anderson MD In Cancer Center, seduceretur ab donata NK cellulis paulatim absumitur totus sanguine et genere machinator exprimere car requiritur quod-cancer can identify specifica peltas. CAR NK cellulis, et non opus est "ornatus" in II, XV, an immune ad augendae cellam proliferation et salvos signaling molecule disposito.
In hoc studio, CAH-sunt allogeneic NK cellulis, quae sunt hae cellulae quo modo, qui sunt ex sana oblatorum ab his patientes estote non patientes estote ad ipsum. Ideo car-NK cellulis habet potentiale ad confici potuit in antecessum et consecravit ea in usum praesentem. E contra, est currently ad commercium available car-T cellulis opus ad uti a septimana multi-culturae propagationem T cellulis processus ad producendum illa quae fundatur in genere machinator patientes estote proprium genes.
In car-t NK cellulis multiplex usus car amet
First, unlike CAR-T cells, CAR-NK cells retain the inherent ability to recognize and target tuberculum cells through their natural receptors, so that when CAR-NK targeted therapy is used, tumor cells are less likely to escape killing.
Second, CAR-NK cells do not undergo immune rejection for days to weeks. As a result, they have not shown the same safety issues in many CAR-T clinical trials, such as the absence of cytokine release syndrome.
Denique NK cellulis non eget stricte matching HLA erectum, nec habet potentiale ad inserere causa est, exercitum versus morbus, qui est magni momenti pro car periculo T-cell immunotherapy.
